These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 25792301)

  • 1. Palbociclib: first global approval.
    Dhillon S
    Drugs; 2015 Apr; 75(5):543-51. PubMed ID: 25792301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palbociclib and Letrozole in Advanced Breast Cancer.
    Finn RS; Martin M; Rugo HS; Jones S; Im SA; Gelmon K; Harbeck N; Lipatov ON; Walshe JM; Moulder S; Gauthier E; Lu DR; Randolph S; Diéras V; Slamon DJ
    N Engl J Med; 2016 Nov; 375(20):1925-1936. PubMed ID: 27959613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
    Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
    Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
    Beaver JA; Amiri-Kordestani L; Charlab R; Chen W; Palmby T; Tilley A; Zirkelbach JF; Yu J; Liu Q; Zhao L; Crich J; Chen XH; Hughes M; Bloomquist E; Tang S; Sridhara R; Kluetz PG; Kim G; Ibrahim A; Pazdur R; Cortazar P
    Clin Cancer Res; 2015 Nov; 21(21):4760-6. PubMed ID: 26324739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palbociclib: A new hope in the treatment of breast cancer.
    Palanisamy RP
    J Cancer Res Ther; 2016; 12(4):1220-1223. PubMed ID: 28169231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
    Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palbociclib improves survival in advanced breast cancer.
    Burki TK
    Lancet Oncol; 2017 Jan; 18(1):e1. PubMed ID: 27890465
    [No Abstract]   [Full Text] [Related]  

  • 8. Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
    Raphael J; Helou J; Pritchard KI; Naimark DM
    Eur J Cancer; 2017 Nov; 85():146-154. PubMed ID: 28930692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.
    Kim ES; Scott LJ
    Target Oncol; 2017 Jun; 12(3):373-383. PubMed ID: 28488183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.
    Clark AS; Karasic TB; DeMichele A; Vaughn DJ; O'Hara M; Perini R; Zhang P; Lal P; Feldman M; Gallagher M; O'Dwyer PJ
    JAMA Oncol; 2016 Feb; 2(2):253-60. PubMed ID: 26633733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
    Walker AJ; Wedam S; Amiri-Kordestani L; Bloomquist E; Tang S; Sridhara R; Chen W; Palmby TR; Fourie Zirkelbach J; Fu W; Liu Q; Tilley A; Kim G; Kluetz PG; McKee AE; Pazdur R
    Clin Cancer Res; 2016 Oct; 22(20):4968-4972. PubMed ID: 27407089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study.
    Masuda N; Nishimura R; Takahashi M; Inoue K; Ohno S; Iwata H; Mori Y; Hashigaki S; Muramatsu Y; Nagasawa T; Umeyama Y; Toi M
    Cancer Sci; 2018 Mar; 109(3):803-813. PubMed ID: 29345736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.
    Bell T; Crown JP; Lang I; Bhattacharyya H; Zanotti G; Randolph S; Kim S; Huang X; Huang Bartlett C; Finn RS; Slamon D
    Curr Med Res Opin; 2016 May; 32(5):959-65. PubMed ID: 26894413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperuricemia in 2 Patients Receiving Palbociclib for Breast Cancer.
    Bromberg DJ; Valenzuela M; Nanjappa S; Pabbathi S
    Cancer Control; 2016 Jan; 23(1):59-60. PubMed ID: 27009458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.
    Kish JK; Ward MA; Garofalo D; Ahmed HV; McRoy L; Laney J; Zanotti G; Braverman J; Yu H; Feinberg BA
    Breast Cancer Res; 2018 May; 20(1):37. PubMed ID: 29720233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
    Finn RS; Crown JP; Ettl J; Schmidt M; Bondarenko IM; Lang I; Pinter T; Boer K; Patel R; Randolph S; Kim ST; Huang X; Schnell P; Nadanaciva S; Bartlett CH; Slamon DJ
    Breast Cancer Res; 2016 Jun; 18(1):67. PubMed ID: 27349747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
    Pritchard KI; Chia SK; Simmons C; McLeod D; Paterson A; Provencher L; Rayson D
    Oncologist; 2017 Jan; 22(1):12-24. PubMed ID: 27864574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribociclib: First Global Approval.
    Syed YY
    Drugs; 2017 May; 77(7):799-807. PubMed ID: 28417244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
    Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
    Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.